High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure
High serum level of pentosidine, an advanced glycation end product (AGE), is a risk factor of patients with heart failure
复制标题
DOI：
10.1016/j.cardfail.2006.11.009
复制
发表时间：
2007-04-01
影响因子：
6
通讯作者：
Kubota, Isao
中科院分区：
文献类型：
--
作者：
Koyama, Yo;Takeishi, Yasuchika;Kubota, Isao
背景：戊糖甙是一种晚期糖基化终产物（AGE），由蛋白质的非酶糖基化和氧化产生。AGE受体（AGE）在多种组织中表达，AGE与AGE的相互作用诱导氧化应激和细胞内信号传导的激活，引起细胞因子和炎症介质的产生。我们调查是否血清pentosidine是一个危险因素，为heartful.Methods和Results：血清pentosidine浓度测定在141例心力衰竭和18例对照组由竞争性酶联免疫吸附试验。在中位随访期479天内对患者进行前瞻性随访，终点为心源性死亡或再住院。纽约心脏协会（NYHA）心功能III/IV级患者的血清戊糖苷酶浓度显著高于NYHA心功能I/II级患者（P
Background: Pentosidine, one of the advanced glycation end products (AGE), is generated by nonenzymatic glycation and oxidation of proteins. The receptor of AGE (RAGE) is expressed in a variety of tissue, and interaction of AGE with RAGE induces oxidative stress and activation of intracellular signaling, causing production of cytokines and mediators of inflammation. We investigated whether serum pentosidine is a risk factor for heart failure.Methods and Results: Serum pentosidine concentration was measured in 141 patients with heart failure and 18 control subjects by a competitive enzyme-linked immumosorbent assay. Patients were prospectively followed during a median follow-up period of 479 days with end points of cardiac death or rehospitalization. Serum concentration of pentosidine was significantly higher in New York Heart Association (NYHA) Class III/IV patients than in NYHA class I/II patients (P